Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic, Mounjaro, and Wegovy. Still, many others are holding out for GLP-1 medication to arrive in pill form—and they may not have to wait much longer.
Orforglipron, a GLP-1 agonist administered as a pill, is developed by pharmaceutical giant Eli Lilly and is among the most highly anticipated oral medicines. (Eli Lilly is also the drugmaker behind Mounjaro, a semaglutide touted by Amy Schumer and Eric Stonestreet, among other celebrities.) The medication, which has shown promising results in clinical trials for weight management, is currently under review by the U.S. Food and Drug Administration (FDA).
While similar drugs are in the review pipeline, Eli Lilly may find its pills pulling away from the pack, thanks to pressure on reviewers from both the drug giant and the FDA to hasten their pace, according to a Reuters report on December 12.
The post New Weight-Loss Pills Could Arrive Sooner Than We Think appeared first on The Daily Beast